Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Painful Diabetic Neuropathies Clear all
Completed Not applicable Interventional Results available

Lidocaine for Diabetic Peripheral Neuropathy

NCT02363803
View directory record Official record
Conditions
Diabetes, Peripheral Neuropathy, Pain
Interventions
lidocaine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 4 Interventional

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159731
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

NCT01056315
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
GRT3938Y, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Fairhope, Alabama • Homewood, Alabama • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 21, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tanezumab, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 4 Interventional

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy

NCT00380913
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Cesamet™ (nabilone)
Drug
Lead sponsor
NEMA Research, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Aventura, Florida • Hollywood, Florida • Naples, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2008 · Synced Jul 21, 2026, 10:18 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

NCT00381719
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
AGN 203818, placebo capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Jul 21, 2026, 10:18 PM EDT
Completed No phase listed Observational

Observational Study of the the Use of a Trigeminal Vagal Nerve Stimulator in the Routine Care of Native Americans With Diabetic Neuropathy Pain. Pain Scores, Drug Use and Glucose Measurements Will be Assessed

NCT07025356
View directory record Official record
Conditions
Diabetic Neuropathy With Neurologic Complication
Interventions
Implantation of a trigeminal Vagus cervical nerve stimulator system, Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation
Drug · Device
Lead sponsor
Vagus Nerve Society
Other
Eligibility
18 Years to 89 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pine Ridge, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

NCT02927951
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Nerve Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
40 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors

NCT00010751
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Reiki
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy

NCT01521598
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
SKL11197, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Northport, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
View directory record Official record
Conditions
Diabetic Neuropathies, Neuropathic Pain, Pain, Chronic
Interventions
Omnitram Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Anaheim, California • Cerritos, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy

NCT02809911
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 10:18 PM EDT
Withdrawn Phase 2 Interventional

Laser Therapy for Diabetic Peripheral Neuropathic Pain

NCT02328911
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Laser treatment, Sham treatment
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jul 21, 2026, 10:18 PM EDT
Withdrawn Not applicable Interventional

Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy

NCT00279266
View directory record Official record
Conditions
Peripheral Neuropathy, Diabetes Mellitus, Diabetes Complications
Interventions
Thiamine
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00143156
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Not applicable Interventional

Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)

NCT02104466
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Acupuncture
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT02427464
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Engensis (VM202), placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 21, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 21, 2026, 10:18 PM EDT